Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European ...

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

Argenx (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the US, Japan, China, the Netherlands, and internationally.

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDPApproval based on ADHERE clinical trial, the ...

The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...

CIDP treatment evolves with novel approvals like Vyvgart Hytrulo and HYQVIA, offering patients new, less invasive and more convenient therapy options. As CIDP moves toward targeted therapies and ...

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...

VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than ...

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare ...

European biotech argenx (Euronext: ARGX) has secured European Commission approval for Vyvgart (efgartigimod alfa) in chronic ...

The Australian swimming legend and triple Olympian opens up about finding hope and courage in the face of a chronic health ...